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An antibody against L1 cell adhesion molecule
inhibits cardiotoxicity by regulating persistent
DNA damage
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Targeting the molecular pathways underlying the cardiotoxicity associated with thoracic
irradiation and doxorubicin (Dox) could reduce the morbidity and mortality associated with
these anticancer treatments. Here, we find that vascular endothelial cells (ECs) with per-
sistent DNA damage induced by irradiation and Dox treatment exhibit a fibrotic phenotype
(endothelial–mesenchymal transition, EndMT) correlating with the colocalization of L1CAM
and persistent DNA damage foci. We demonstrate that treatment with the anti-L1CAM
antibody Ab417 decreases L1CAM overexpression and nuclear translocation and persistent
DNA damage foci. We show that in whole-heart–irradiated mice, EC-specific p53 deletion
increases vascular fibrosis and the colocalization of L1CAM and DNA damage foci, while
Ab417 attenuates these effects. We also demonstrate that Ab417 prevents cardiac
dysfunction-related decrease in fractional shortening and prolongs survival after whole-heart
irradiation or Dox treatment. We show that cardiomyopathy patient-derived cardiovascular
ECs with persistent DNA damage show upregulated L1CAM and EndMT, indicating clinical
applicability of Ab417. We conclude that controlling vascular DNA damage by inhibiting
nuclear L1CAM translocation might effectively prevent anticancer therapy-associated
cardiotoxicity.
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Radiation therapy and the anthracycline chemotherapy drugdoxorubicin (Dox; trade name: Adriamycin) are commonlyprescribed anticancer treatments1. However, the DNA
damage caused by these therapies is associated with cardiotoxi-
city, which causes congestive heart failure and cardiovascular
complications and limits the use of these therapies1. Indeed, a
meta-analysis revealed excess mortality owing to heart disease in
women receiving radiation therapy for left-sided breast cancer2,3.
In the case of Dox, the risk and severity of cardiotoxicity is dose
dependent4,5 and dosage increases to improve cancer outcomes
are often associated with increased cardiovascular morbidity and
mortality6,7. Targeting the molecular pathways underlying this
cardiotoxicity could help prevent or control such cardiac com-
plications after anticancer therapy. As a chelator of intracellular
iron, dexrazoxane, an FDA-approved drug, prevents Dox-induced
heart failure from interfering with the anti-tumour effect of Dox8.
A recent study also reported that a small molecule allosteric
inhibitor of BAX and a compound that stabilises tetrameric
PKM2 prevent Dox-induced cardiomyopathy9,10; However, there
are still no clinical therapies to efficiently prevent Dox-induced
cardiotoxicity.
After radiation therapy, damage to the cardiac micro-
vasculature occurs, potentially within days or months11.
Radiation-induced microvascular ischaemia disrupts capillary
endothelial cells (ECs), and injury to differentiated cardiomyo-
cytes results in collagen deposition and fibrosis, which progress to
cardiovascular disease12. In addition, endothelial dysfunction,
inflammation, DNA damage, oxidative stress, and altered coa-
gulation and platelet activity may play important roles in
radiation-induced cardiovascular effects13,14. The pathogenesis of
Dox cardiotoxicity has been suggested to involve DNA damage,
transcriptome alteration, mitochondrial iron accumulation,
mitochondrial damage, vascular endothelial injury, and reactive
oxygen species (ROS) accumulation15,16.
L1 cell adhesion molecule (L1CAM; also known as CD171) is a
transmembrane glycoprotein belonging to the Ig superfamily of
cell adhesion molecules (CAMs). It consists of a cytoplasmic
intracellular domain, a transmembrane domain, and an extra-
cellular region comprising six Ig-like domains and five fibronectin
type III domains17,18. The L1CAM extracellular domains interact
with other L1CAM molecules, growth factor receptors, integrins,
neuropilin-1, and extracellular matrix proteins19,20. L1CAM has
been reported to exhibit important functions in different cells and
tissues, including neurites, kidney tubule epithelial cells, lym-
phoid and myelomonocytic cells, and intestinal crypt cells17,21–25.
NCAM plays an important role in cell adhesion through het-
erophilic interactions with L1CAM. Moreover, neural cell adhe-
sion molecule (NCAM) was found to be upregulated upon
metabolic stress in cardiomyocytes26 and reported to be asso-
ciated with cardiac vascular development27. NCAM genetic var-
iants have been demonstrated to be important heritable
predictors of cardiovascular disease, such as hypertension28.
During hypertension-induced LV remodelling, which leads to
heart failure, NCAM was found to be highly expressed27. Notably,
Nagao et al.29 showed that NCAM may be involved in LV
remodelling with heart failure in a study conducted using 64
human cardiac tissue samples of patients with dilated cardio-
myopathy. Further, L1CAM has been shown to have a function in
cancer, as it promotes the proliferation, migration, invasion, and
chemoresistance of tumour cells30,31, and its expression is cor-
related with poor prognosis and metastases in various cancers19.
Moreover, it has been reported that the L1CAM intracellular
domain is cleaved from the membrane-bound portion of
L1CAM by ADAM10 and γ-secretase, after which it is translo-
cated to the nucleus to regulate the expression of genes involved
in tumour progression32. Additionally, nuclear L1CAM signalling
augments the DNA damage checkpoint response and radio-
resistance of glioblastoma stem cells33. It has been reported
that L1CAM regulates tumour vascular permeability and
endothelial–mesenchymal transition (EndMT) in pancreatic
carcinoma34. To study anti-L1CAM antibodies as anticancer
agents, we previously developed a human mAb, Ab417, that binds
to human and mouse L1CAM with high affinity35,36. Here, we
show the involvement of L1CAM in the DNA damage response
in vascular ECs and the therapeutic efficacy of Ab417 against
DNA damage-induced cardiotoxicity.
Results
Nuclear L1CAM is involved in persistent DNA damage in ECs.
We have previously reported that vascular ECs undergo EndMT
during radiation-induced atherosclerosis and pulmonary
fibrosis37,38. Additionally, CAMs on ECs have been reported to
play an important role in radiation-induced vascular damage and
EndMT39,40. To explore the roles of CAMs in regulating
radiation-induced cardiovascular disease, we performed micro-
array analysis on cardiac ECs. We found that L1CAM expression
in cardiac ECs was upregulated by 2.1-fold 12 h after irradiation
(Supplementary Fig. 1a). In addition, irradiation increased the
protein expression of L1CAM in vascular ECs along with that of
α-SMA (a fibroblastic marker) and VCAM-1 (an important CAM
involved in leucocyte trafficking) (Supplementary Fig. 1b), indi-
cating that EndMT is occurring in response to irradiation.
Importantly, these effects were efficiently inhibited when L1CAM
was knocked down with small-interfering RNA ((siRNA); Sup-
plementary Fig. 1b), suggesting that L1CAM is involved in
EndMT in response to irradiation. To further confirm
these observations, we next examined the effects L1CAM inhi-
bition on irradiation-induced transendothelial migration of
human monocytes, a marker of the inflammatory response. We
found that treatment with the anti-L1CAM mAb
Ab417 significantly inhibited the transendothelial migration 24 h
after irradiation (Supplementary Fig. 1c). These data indicate that
L1CAM may be an effective regulator of radiation-induced vas-
cular damage.
Next, we examined whether radiation-induced DNA damage
can affect EndMT. Immunofluorescence experiments in human
umbilical vein endothelial cells (HUVECs) indicated that the
severity of the elongated fibrotic phenotype (marked by
phalloidin, showing actin cytoskeleton reorganisation was
correlated with the number of DNA damage foci (marked by γ-
H2AX) 48 h after 2 Gy, 5 Gy or 10 Gy of irradiation, and this
correlation was dose dependent (Fig. 1a). This was accompanied
by dose-dependent colocalization of nuclear L1CAM-C-terminus
(L1-CT) with γ-H2AX foci, a marker of DNA double-strand
breaks (Fig. 1b). Furthermore, RNA-sequencing (RNA-seq)
analysis showed that the expression of EndMT-related genes
was higher in 10 Gy-irradiated cells 72 h after irradiation than in
10 Gy-irradiated cells 5 h after irradiation or in non-irradiated
cells (Fig. 1c). The average number of γ-H2AX foci per cell at
least 70 cells per field increased from 1 to 59 at 1 h post-
irradiation, and then decreased to 26 at 48 h post-irradiation
(Fig. 1d), indicating persistent DNA damage in the cells.
However, the intensity and foci diameter were significantly
decreased at 24 h and after increased again thereafter (Supple-
mentary Fig. 2a). The number of γ-H2AX foci with an intensity
larger than 40 and a foci diameter of 0.1 μmwas counted (Fig. 1d).
Live-cell imaging was used to confirm the persistence of
DDR foci, and 53BP1 DNA damage foci were traced in
HUVECs transfected with GFP-53BP1 (a marker of DNA
damage foci); Kaplan–Meier survival curves for GFP-positive
foci were analysed from 12 h after 10 Gy irradiation, showing
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that 64 % of GFP-positive foci had a lifespan of over 48 h
(Supplementary Fig 2b).
Nuclear L1-CT foci were detected by the binding of an anti-
L1CAM antibody to the C-terminal epitope but not to the N-
terminal epitope (Fig. 1b, d), which demonstrates that the nuclear
L1-CT foci were derived from L1-CT cleaved from L1CAM.
Altogether, we suggest that nuclear localisation of L-CT is
correlated with persistent DNA damage, accompanied with
radiation-induced EndMT.
Next, we investigated the effect of nuclear L1-CT on
radiation-induced persistent DNA damage in vascular ECs.
The expression levels of intact L1CAM (250 kDa) and L1-CT
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fragments (32–37 kDa) were higher in 10 Gy irradiation-treated
cells 48 h post-irradiation than in untreated cells and were
lower in L1CAM lentiviral shRNA-transfected cells than in
control shRNA-transfected cells 48 h post-irradiation (Fig. 1e).
According to immunofluorescence analysis, we used the
lentiviral shRNA to knockdown L1CAM to show that the the
L1-CT and γ-H2AX colocalization disappeared, indicating that
this colocalization was dependent on L1CAM expression.
(Fig. 1e, bottom panel). Similarly, higher expression of cytosolic
L1CAM and nuclear L1-CT was observed in irradiated
HUVECs than in untreated cells, but Ab417 treatment
attenuated this radiation-mediated increase in expression 48 h
after irradiation (Fig. 1f). These results were confirmed by
immunofluorescence showing that Ab417 efficiently decreased
the nuclear localisation of L1-CT in HUVEC-irradiated cells
(Fig. 1g). Importantly, this was accompanied by a reduction in
the number of γ-H2AX foci and, consequently, the number of
colocalized L1-CT and γ-H2AX foci (Fig. 1g). Furthermore,
Ab417 pre-treatment resulted in a significant reduction in the
elongated fibrotic phenotype of HUVECs 72 h after irradiation,
showing reduced size of irradiated ECs with flattened nuclei
compared to non-irradiated ECs (Fig. 1h and Supplementary
Fig. 2c). Although Ab417 did not significantly affect radiation-
induced cell death, it significantly increased the proliferation
rate and reduced the aneuploid cell population 120 h after
irradiation (Supplementary Fig. 2d, e), indicating that persistent
DNA damage in ECs may be related to aneuploidy and a
morphological change from normal to fibrotic ECs. Addition-
ally, we found that in prolonged culture (up to 40 days
following irradiation), Ab417-treated ECs prominently sus-
tained reduced DNA damage and aneuploidy compared to IgG-
treated ECs, The number and intensity of L1-CT foci were also
decreased at longer time points in Ab417-treated cells,
compared to IgG-treated ECs (Supplementary Fig. 2f). These
results suggest that Ab417 regulates radiation-induced persis-
tent DNA damage and the fibrotic changes in ECs.
Finally, we examined whether L1CAM can also regulate Dox-
induced DNA damage in HUVECs. As expected, γ-H2AX foci
were detected 1 h after Dox treatment and increased in number
after 6 h (Supplementary Fig. 2g), confirming that Dox induces
persistent DNA damage. L1-CT colocalized with γ-H2AX foci 24
h after Dox treatment, which was significantly reduced by Ab417
treatment (Fig. 1i). Ab417 also did not significantly affect Dox-
induced cell death, it significantly increased the proliferation
(Supplementary Fig. 2h). Dox treatment also enhanced fibrotic
cytoskeletal development (Fig. 1j); and increased L1CAM, α-
SMA, VCAM-1 and γ-H2AX expression (Supplementary Fig. 2i),
and these effects were inhibited by Ab417 treatment (Fig. 1j and
Supplementary Fig 2i).
Taken together, our findings suggest that nuclear L1-CT
regulates radiation- and Dox-induced persistent DNA damage via
colocalization with γ-H2AX foci in vascular ECs with a fibrotic
phenotype.
Nuclear L1CAM foci directly regulate persistent DNA damage
repair in ECs. Next, we studied the precise role of nuclear L1-CT
in the DNA damage response in vascular ECs. First, we studied if
L1CAM cleavage was necessary for and L1-CT and γ-H2AX foci
colocalization. To this end we used the inhibitor L-685,458, which
is known to inhibit L1CAM cleavage by presenilin (γ-
secretase)41,42, and found that inhibition of the γ-secretase in
irradiated HUVECs resulted in decreased radiation-induced
L1CAM overexpression, L1-CT levels, and L1-CT and γ-H2AX
foci colocalization (Fig. 2a).
Next, to examine the functional role of cleaved nuclear L1-CT,
we generated an L1-4A mutant construct with a mutation in the
previously described L1CAM nuclear localisation signal
(NLS)43,44 and an endocytosis-deficient L1CAM mutant lacking
Fig. 1 L1-CT fragments colocalize with persistent γ-H2AX foci after irradiation (IR) or Dox treatment in HUVECs. a, b Immunofluorescence staining and
quantification of phalloidin, γ-H2AX and L1-CT 48 h post IR (2 Gy, 5 Gy, or 10 Gy) in HUVECs (left panels, magnification, ×400). Scale bar= 20 µm
(enlarged, 5 µm). Bar graphs quantifying the number of γ-H2AX foci, the phalloidin density, and the number of colocalized foci (right panels). For
quantification of phalloidin density, error bars represent mean ± SEM (2 Gy vs. 10 Gy p < 0.0001; 5 Gy vs. 10 Gy p= 0.0015). For quantification of the
number of γ-H2AX foci, error bars represent mean ± SD (****p < 0.0001). Colocalized foci (marked by white arrow) are amplified and graphs represent
quantification of L1-CT and γ-H2AX signals in selected regions of dotted lines (bottom panels). Error bars represented mean ± SEM (****p < 0.0001).
c Heat map of the RNA-seq analysis results showing radiation-induced EndMT and the mesenchymal phenotype. Total RNA was isolated from HUVECs
before and after 10 Gy IR (5 h, 72 h). d Immunofluorescence staining of L1-CT and γ-H2AX in HUVECs at 0, 1, 24, and 48 h post IR (10 Gy; left panels).
Quantification of γ-H2AX foci and nuclear L1CAM (magnification, ×400; right panels). The number of γ-H2AX foci with an intensity greater than 40 and a
foci diameter of 0.1 μm was counted. Scale bar= 20 µm (enlarged, 5 µm). e Immunoblotting and quantification of full-length L1CAM and L1-CT fragments
from HUVECs transfected with lentiviral shRNA targeting L1CAM 48 h after IR (10 Gy; upper panels). Error bars represent mean ± SD (full-length L1CAM:
sh-Control IR – vs.+ p= 0.0003; sh-Control IR+ vs. sh-L1CAM IR+ p < 0.0001, L1-CT fragments: sh-Control IR – vs.+ p= 0.0013; sh-Control IR+ vs. sh-
L1CAM IR+ p= 0.0006). Immunofluorescence staining of γ-H2AX and L1-CT 48 h post IR (10 Gy) in HUVECs (magnification, ×400). Scale bar= 5 µm.
f Immunoblotting (upper panel) of full-length L1CAM and L1-CT fragments in the cytoplasmic (C) and nuclear (N) fractions of HUVECs 48 h post IR (10
Gy). Quantification of full-length L1CAM in the cytoplasmic fractions and L1-CT fragments in the nuclear fractions. HUVECs were treated with control IgG
or Ab417 (20 µg/mL) before IR. GAPDH and lamin B were used as cytoplasmic and nuclear markers, respectively. Error bars represent mean ± SD from
independent experiments (full-length L1CAM: No IR vs. IR+ IgG p < 0.0001; IR+ IgG vs. IR+Ab417 p= 0.0001, L1-CT fragments: No IR vs. IR+ IgG p=
0.0228; IR+ IgG vs. IR+Ab417 p= 0.0448). g Immunofluorescence staining for L1-CT and γ-H2AX 0 and 48 h post IR (10 Gy) in HUVECs pre-treated
with control IgG or Ab417 (20 µg/mL) (upper panel). Quantification of colocalization of γ-H2AX foci with L1CAM (magnification, ×400) (lower panel).
Scale bar= 20 µm (enlarged, 5 µm). h Immunofluorescence staining (upper panel) and quantification (lower panel) of phalloidin and L1-CT 72 h post IR
(10 Gy) in HUVECs pre-treated with control IgG or Ab417 (20 µg/mL; magnification, ×400). Scale bar= 20 µm. Error bars represent mean ± SD (p=
0.0007). i Immunofluorescence staining for L1-CT and γ-H2AX at 0 and 24 h after Dox treatment in HUVECs pre-treated with control IgG or Ab417 (20
µg/mL; left panel). Colocalized foci (marked by white arrow) are amplified and graphs represent quantification of L1-CT and γ-H2AX signals in selected
regions of dotted lines (middle panels). Quantification of colocalization of γ-H2AX foci with L1CAM (magnification, ×400; right panel). Scale bar= 5 µm.
j Immunofluorescence staining and quantification of phalloidin and γ-H2AX 0 and 24 h after Dox treatment in HUVECs pre-treated with control IgG or
Ab417 (magnification, ×400). Scale bar= 10 μm. Error bars represent mean ± SD (IgG vs. Dox+ IgG p= 0.0002; Dox+ IgG vs. Dox+Ab417 p= 0.0482;
Ab417 vs. Dox+Ab417 p= 0.0065). For quantification of γ-H2AX foci and γ-H2AX foci colocalized with L1CAM, the foci in each sample were counted at
least 70 cells per field (magnification, ×100). The average number of foci/cell was determined from >6 fields (magnification, ×100). Data are
representative of three independent experiments. (h: two-talied Student’s t-test, all other panels: one-way ANOVA for multiple comparisons).
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the RSLE motif (L1-dRSLE) (Fig. 2b), which is involved in
clathrin-mediated L1CAM endocytosis and cleavage45. To
minimise the effect of endogenous wild-type L1CAM, we
suppressed L1CAM expression using lentivirus-expressed shRNA
specific for L1CAM. At 48 h post-irradiation, compared with L1-
WT-expressing HUVECs, L1-4A- or L1-dRSLE-overexpressing
HUVECs showed a significant reduction in the number of L1-CT
foci and this was accompanied by a significant reduction in
numbers of γ-H2AX foci and, consequently, in the number of
colocalized foci (Fig. 2b). Moreover, HUVECs expressing L1-4A
and L1-dRSLE did not show the radiation-induced fibrotic
changes observed in L1CAM-expressing HUVECs (Fig. 2c).
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Consistent with the fibrotic changes observed with phalloidin
staining, overexpression of L1-WT, but not L1-4A or L1-dRSLE,
significantly increased radiation-induced collagen type 1
(COL1A1) and α-SMA expression above the levels observed in
the irradiated controls (Supplementary Fig. 3a). From these
results, we suggest that L1CAM cleavage regulates the DNA
damage via nuclear L1-CT and γ-H2AX foci colocalization and
the fibrotic changes in irradiated ECs.
We then aimed to determine whether nuclear L1-CT directly
regulates the DNA damage response in vascular ECs. To this end
first we investigated whether L1-CT foci colocalized with DNA
repair enzymes, namely, the homologous recombination (HR)
markers phospho-ATM (p-ATM) and 53BP1 and the non-
homologous end joining (NHEJ) marker DNA-PKcs, following
irradiation. Indeed we detected colocalization of L1-CT foci with
p-ATM, 53BP1, and DNA-PKcs at 48 h post-irradiation in
control cells treated with IgG and this colocalization was
significantly reduced in cells pre-treated with Ab417 (Fig. 2d
and Supplementary Fig. 3b). To determine whether L1-CT is
recruited to the targeted DNA damage site, we studied L1-CT and
γ-H2AX foci colocalization in HUVECs after causing site-specific
DNA damage using laser microirradiation and found that L1-CT
was recruited to the γ-H2AX foci 20 min after microirradiation
(Supplementary Fig. 3c). We next investigated whether L1-CT
directly regulates double-strand break repair via HR or NHEJ
using the previously described DR-GFP and EJ5-GFp reporters of
HR and NHEJ, respectively46–48. In these reporters, the GFP
genes contain a cut sites for the I-SceI nuclease, whose activity
causes a double-strand break; repair of the double-strand break
by HR and NHEJ restores the DR-GFP and EJ5-GFP genes,
respectively, resulting in functional GFP proteins. We transfected
DR-GFP and EJ5-GFP into HUVECs treated with or without
L1CAM-specific siRNA and found that the percentages of DR-
GFP+ and EJ5-GFP+ cells among L1CAM-specific siRNA-treated
cells were significantly higher (over 2- and 1.5-fold higher,
respectively) than those among control siRNA-treated cells
(Fig. 2e and Supplementary Fig. 3d), indicating that L1-CT is
required for both HR and NHEJ repair. As L1-CT fragments are
produced via cleavage after DNA damage, we generated 32 kDa
GFP-tagged L1-CT. Compared with L1CAM, GFP-tagged L1-CT
increased the number of γ-H2AX foci and enhanced the
transition to a fibrotic phenotype after irradiation (Fig. 2f).
Consistent with these results, an immunoprecipitation assay
showed that L1-CT binds to r-H2AX in irradiated ECs
transfected with GFP-L1-CT (Supplementary Fig. 3e).
Collectively, the findings suggest that L1-CT is required for the
DNA repair process via colocalization with γ-H2AX foci in
vascular ECs.
Ab417 promotes the endocytic internalisation and lysosomal
degradation of L1CAM. In accordance with our previous work36,
Ab417 inhibited the expression levels of full-length L1CAM and
its C-terminal fragment in this study. L1CAM has also been
reported to be regulated by its lysosomal degradation and
endocytosis49. To clarify how Ab417 directly affects L1CAM
levels, we examined the effects of Ab417 on the endocytosis and
lysosomal degradation of L1CAM. Ab417 was labelled with
pHrodro fluorescence dye, which increases fluorescence upon
internalisation into acidic endosomes and lysosomes. The red
fluorescence of internalised pHrodo-labelled Ab417 was observed
at 1 h and peaked at 18 h after incubation in HUVECs (Supple-
mentary Fig. 4a). Additionally, we examined whether Ab417 can
directly induce the endocytotic internalisation of endogenous
L1CAM, resulting in lysosomal degradation. An anti-L1CAM
antibody against endogenous L1CAM was labelled with green
pHrodo dye. The pHrodo Green-labelled anti-L1CAM antibody
colocalized with endocytic vesicles containing Ab417 with red
fluorescence (Supplementary Fig. 4a), suggesting that Ab417
induced the internalisation and endocytosis of membrane
L1CAM. Ab417 significantly reduced L1CAM expression in WT-
L1CAM-overexpressing HUVECs, and this effect was inhibited
by treatment with the lysosomal degradation inhibitor
bafilomycin-A1 (Supplementary Fig. 4b,c). These results suggest
Fig. 2 Nuclear localisation of L1CAM inhibits γ-H2AX foci resolution and DNA repair in HUVECs. a Immunofluorescence staining and quantification of γ-
H2AX foci colocalized with L1-CT (upper left panel; magnification, ×400) and immunoblotting (lower left panel) and quantification (right panels) of full-
length L1CAM, L1-CT fragments, and γ-H2AX at 48 h post-irradiation (10 Gy) in HUVECs with or without γ-secretase inhibitor L-685,458 (3 µM)
treatment. For quantification of γ-H2AX foci colocalized with L1-CT, error bars represent mean ± SEM (p= 0.0017). For quantification of full-length L1CAM
and L1-CT fragments, error bars represent mean ± SD (full-length L1CAM: (-) vs. IR p= 0.0011; IR vs. IR+ L-685,458 p= 0.0233, L1-CT fragments: (-) vs.
IR p= 0.0017; IR vs. IR+ L-685,458 p= 0.0177). b, c HUVECs were transfected with human full-length (L1-WT), NLS-mutated (L1-4A), and endocytosis-
deficient (L1-dRSLE) L1CAM vectors after knockdown of endogenous L1CAM. b Scheme of L1-WT, L1-4A and L1-dRSLE constructs (top left panel).
Immunoblotting of full-length L1CAM in HUVECs (top right panel) and immunofluorescence staining (middle panels) and quantification (bottom panels) of
L1-CT and γ-H2AX in HUVECs 48 h post-irradiation (10 Gy; magnification, ×400). Scale bar= 5 µm. Error bars represent mean ± SEM (No. γ-H2AX foci:
Control vs. L1CAM-WT p= 0.001; L1CAM-WT vs. L1CAM-4A p= 0.0001; L1CAM-WT vs. L1CAM-dRSLE p= 0.0002, No. L1-CT foci: ****p < 0.0001;
L1CAM-WT vs. L1CAM-dRSLE p= 0.0004, No. colocalized foci: Control vs. L1CAM-WT p= 0.006; ****p < 0.0001). c Immunofluorescence staining and
quantification of phalloidin and γ-H2AX in HUVECs 48 h post-irradiation (10 Gy; magnification, ×400). Scale bar= 20 µm. Error bars represent mean ± SD
(Control vs. L1CAM-WT p= 0.0096; L1CAM-WT vs. L1CAM-4A p= 0.0014; ****p < 0.0001). d Immunofluorescence staining and pearson’s correlation
coefficient of L1-CT colocalized with p-ATM, 53BP1, and DNA-PKcs in the nuclei of Ab417-pre-treated HUVECs 48 h post-irradiation (10 Gy magnification,
×400). Scale bar= 5 µm. Error bars represent mean ± SD (****p < 0.0001). e Flow cytometry analysis of cells with GFP positivity resulting from DNA repair
and quantification of HR (upper panel) and NHEJ (lower panel) efficiency in L1CAM-knockdown HUVECs. The HUVECs were transiently transfected with
the DR-GFP or EJ5-GFP construct along with control or L1CAM siRNA and were then transfected with a SceI plasmid to induce DNA damage. Error bars
represent mean ± SD (HR efficacy p= 0.0005, NHEJ efficacy p= 0.0011). f Immunofluorescence staining (upper panel) for GFP, phalloidin, γ-H2AX in
HUVECs 48 h post-irradiation (10 Gy). Quantification of phalloidin is shown (magnification, ×400; right panel). Scale bar= 20 µm. Error bars represent
mean ± SD (No IR vs. IR+ Control p= 0.0001; IR+ Control vs. IR+ L1CAM-WT p= 0.0063; IR+ L1CAM-WT vs. IR+ L1CAM-C-term p= 0.0027, IR+
Control vs. IR+ L1CAM-C-term p < 0.0001). HUVECs were transfected with L1-WT or L1-CT lentiviral vectors tagged with N-terminal GFP and C-terminal
His. Transfection efficiency (left panel) was tested by immunoblotting for L1-WT and L1-CT. For quantification of foci colocalized with L1CAM, the
colocalized foci in each sample were counted in a minimum of 70 cells per field (magnification, ×100). The average number of colocalized foci/cell was
determined from five fields (magnification, ×100). The data are presented the means ± SDs and ±SEMs from three independent experiments. (a upper left
panel: two-talied Student’s t-test; a all other panels and b, c, f: one-way ANOVA for multiple comparisons; d, e two-way ANOVA for multiple
comparisons).
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that Ab417 promotes the internalisation, endocytosis and sub-
sequent lysosomal degradation of L1CAM in HUVECs.
Additionally, to address the possibility of unwanted effects by
Ab417, we performed an NK cell-mediated antibody-dependent
cellular cytotoxicity (ADCC) assay to determine whether Ab417
on HUVECs can lead to effector function. Ab417 on HUVECs
did not trigger the ADCC effect, and the ADCC effect of the anti-
CD20 antibody on Raji cells was used as a positive control
(Supplementary Fig. 4d). This result supports our data that
Ab417 protects against EC damage following radiation and Dox
treatment without ADCC effects.
Altogether, our findings suggest that Ab417 reduced L1CAM
expression by the endocytotic lysosomal degradation of full-
length L1CAM and subsequently reduced the expression of the
L1-CT fragment. Therefore, the Ab417 antibody inhibits
persistent DNA damage by reducing the expression of full-
length L1CAM and the subsequent nuclear L-CT fragment and
does not directly interfere with the cleavage and nuclear
translocation of L1CAM.
The anti-L1CAM antibody reduces p53 knockout- and radia-
tion- and Dox-induced DNA damage in cardiovascular ECs. As
the results of the above subsection indicated that L1-CT regulates
the DNA repair process in vascular ECs, we next investigated
whether the anti-L1CAM antibody can prevent radiation-induced
cardiac damage. We specifically examined cardiac damage
enhanced by EC-p53 deletion, as endothelial p53 deletion has
been reported to enhance radiation-induced cardiac damage50,51.
To this end, first we examined the effect of p53 expression on
L1CAM expression and nuclear localisation. HUVECs were
transfected with p53-specific siRNA or control siRNA and irra-
diated; 48 h post-irradiation, HUVECs transfected with p53-
specific siRNA showed significantly (fivefold) higher L1CAM
mRNA levels than HUVECs transfected with control siRNA
(Fig. 3a). These results were confirmed at the protein level,
showing that p53 knockdown markedly increased L1-CT and full-
length L1CAM expression after irradiation; and this effect was
inhibited by Ab417 treatment (Fig. 3b). Moreover, immuno-
fluorescence data showed that p53 knockdown markedly
increased the number of L1-CT foci and the colocalization of
these foci with γ-H2AX after irradiation, and that these effects
were reversed in Ab417-treated cells (Fig. 3c and Supplementary
Fig. 5a). p53 knockdown in HUVECs increased radiation-induced
cell death and decreased cell proliferation reduced by irradiation,
and these effects were reversed in Ab417-treated cells (Supple-
mentary Fig 5b).
After confirming that p53 can affect L1CAM expression and
translocation to the nucleus, we next investigated whether Ab417
can prevent irradiation- or Dox-induced DNA damage in p53-
deficient cardiovascular ECs using EC-specific Trp53 knockout
(EC-p53KO) mice (Tie2-Cre;Trp53flox/flox). Compared with wild-
type mice, non-irradiated EC-p53KO mice did not show any
significant differences in arterial wall thickness, vascular fibrosis,
microvessel density, or myocardial dilation (Supplementary
Fig. 5c). By contrast, at 3 weeks after whole-heart irradiation,
DNA damage, nuclear L1-CT and the colocalization of L1-CT
and γ-H2AX in cardiovascular ECs of control IgG-treated EC-
p53KO mice were increased compared to those of wild-type
mice. Importantly, these effects in EC-p53KO irradiated mice
were reversed by Ab417 treatment (Fig. 3d and Supplementary
Fig. 5d, e).
In irradiated cardiac tissues of WT mice, ECs (7.1-fold) were
more γ-H2AX-positive than cardiomyocytes (3.4-fold), compared
to non-irradiated cardiac tissues, and these phenotypes were
enhanced in the irradiated cardiac tissues of pEC-53 KO mice;
additionally, Ab417 reduced DNA damage in ECs to a greater
extent than cardiomyocytes in the irradiated cardiac tissues of
pEC-53 KO mice (Supplementary Fig. 5f).
Consistent with these findings, histological analyses showed
that the radiation-induced increases in inflammation, vascular
fibrosis, arterial wall thickness, and vessel destruction observed in
EC-p53KO mice were efficiently ameliorated by Ab417 treatment
(Fig. 3e). Moreover, the increase in EndMT, measured as number
of α-SMA+CD31+ cells (Fig. 3f), and in hypoxic regions of
cardiomyocytes (Supplementary Fig. 5g) in irradiated EC-p53KO
hearts compared with irradiated wild-type hearts were attenuated
by Ab417 treatment. The cardiac troponin T (cTnT) levels were
also significantly lower in the heart tissues of irradiated EC-
p53KO mice than in those of non-irradiated and irradiated wild-
type mice, but these effects were attenuated by Ab417 (Fig. 3g).
These findings indicate that EC-p53KO affects hypoxia and
cardiomyocyte dysfunction and enhances radiation-induced
EndMT, but these effects were reduced by Ab417 treatment.
Finally, given that Ab417 treatment ameliorated detrimental
irradiation-induced effects in EC-p53KO mouse hearts, we
investigated the effect of Ab417 treatment on Dox-induced
toxicity in EC-p53KO mice. Five days after Dox treatment, we
observed that the DNA damage and nuclear L1-CT levels in
cardiovascular ECs of control IgG-treated EC-p53KO mice were
significantly increased compared with those of wild-type mice;
however, these effects were not observed in Ab417-treated EC-
p53KO mice (Supplementary Fig. 6a). Collectively, these results
indicate that the anti-L1CAM antibody efficiently inhibits the
L1CAM nuclear localisation and DNA damage induced by EC-
p53 deletion. Consistent with the DNA damage in ECs, EndMT
and TnT loss occurred in hypoxic cardiomyocytes, but these
effects were reduced by Ab417 treatment.
Ab417 inhibits radiation- and Dox-induced cardiovascular
DNA damage and EndMT. We next investigated whether
L1CAM affects cardiovascular DNA damage during radiation-
and Dox-induced cardiotoxicity. Whole-heart irradiation of mice
with 16 Gy specifically increased the expression of L1CAM and γ-
H2AX in vascular ECs compared to that in non-irradiated ECs,
and this effect was reversed by Ab417 treatment (Fig. 4a). In the
irradiated hearts of control IgG-treated mice, γ-H2AX foci were
prominently detected in CD31+ ECs and the numbers of these
foci were markedly reduced after Ab417 treatment. (Supple-
mentary Fig. 7a). However, γ-H2AX foci were much less abun-
dant in WGA-stained cardiomyocytes or in α-SMA+ fibroblasts,
compared to podocalyxin+ ECs (Supplementary Fig. 7a, b).
Moreover, histopathological examination showed that heart
irradiation caused vascular fibrosis around the arteriole, large
vessel destruction, and reduced microvessel density, and these
vascular damage patterns were significantly inhibited by Ab417
treatment (Fig. 4b). Furthermore, Ab417 treatment reduced the
radiation-induced increases in inflammatory cell infiltration
around the irradiated vessels (Fig. 4b). Serum levels of C-reactive
protein (CRP), E-selectin, and ICAM-1 (circulating markers of
vascular inflammation), which were higher in irradiated control
IgG-treated mice than in non-irradiated mice, were also sig-
nificantly reduced by Ab417 treatment (Fig. 4c). Antibodies
against L1-CT showed enhanced specificity for vascular endo-
thelial L1CAM in IgG-treated irradiated hearts (Fig. 4d); by
contrast, antibodies against the N-terminal domain did not spe-
cifically target vascular ECs; rather, binding of these antibodies
was broadly detected in the tissue, similar to the general pattern
of secretory factor binding (Supplementary Fig. 7c). Notably,
nuclear L1-CT was predominantly detected in cardiovascular ECs
in irradiated mice but was much less abundant in Ab417-treated
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mice (Fig. 4d and Supplementary Fig. 7d). Furthermore, L1-CT
was more highly expressed in ECs than in the cardiomyocytes or
fibroblasts of either non-irradiated or irradiated mice (Supple-
mentary Fig. 7d, e). EndMT and TnT loss in hypoxic cardio-
myocytes occurred in irradiated mice, but these effects were
reduced by Ab417 treatment (Fig. 4e and Supplementary Fig. 7f).
When similar experiments were conducted in Dox-treated
mice, an induction in L1CAM expression and DNA damage in
vascular ECs was observed (Fig. 4f). Additionally, compared with
untreated controls, Dox-treated mice displayed increased vascular
occlusion, inflammation, arterial wall thickness, and fibrosis along
with a reduced microvessel density (Fig. 4g). Notably, Ab417
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treatment significantly inhibited this Dox-induced cardiac
damage. In addition, Ab417 treatment significantly lowered
Dox-induced serum CRP and E-selectin levels but the not serum
ICAM-1 level (Fig. 4h). Similar to results observed in irradiated
cardiac vessels, Dox-treated cardiovascular ECs showed promi-
nent nuclear L1-CT localisation, which was prevented by Ab417
treatment (Fig. 4i). Dox also induced vascular EndMT and TnT
loss in hypoxic cardiomyocytes, and the effects were prevented by
Ab417 treatment (Fig. 4j and Supplementary Fig. 7g).
Taken together, our findings suggest that Ab417 can prevent
the vascular endothelial damage occurring during radiation- and
Dox-induced cardiotoxicity.
The anti-L1CAM antibody mitigates radiation- and Dox-
induced cardiotoxicity. To assess whether irradiated ECs and
endothelial L1CAM can affect cardiomyocyte damage, induced
pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) were
co-cultured with irradiated ECs with a fibrotic phenotype or with
non-irradiated ECs (Fig. 5a, upper panel). Compared to co-
culture with non-irradiated ECs, co-culture with irradiated ECs
significantly reduced the iPSC-CM beating rate and this effect was
reversed when irradiated ECs transfected with L1CAM-specific
siRNA were used (Fig. 5a, Supplementary Fig. 8a and Supple-
mentary Movies 1–3). In addition, the cTnT levels were sig-
nificantly decreased in iPSC-CMs co-cultured with irradiated ECs
but not in iPSC-CMs co-cultured with L1CAM-knockdown
irradiated ECs (Fig. 5b, top). In the absence of co-culture, TnT
expression was detected in myocytes, but not in irradiated ECs
(Supplementary Fig. 8b). We examined whether the loss of TnT
in cardiomyocytes was caused by cardiomyocyte death using
TUNEL staining (Supplementary Fig. 8c). Apoptotic cells were
not detected in cardiomyocytes but were detected in 7.5 % of
irradiated ECs, indicating that TnT loss is not dependent on cell
death.
Moreover, compared to co-culture with non-irradiated ECs,
co-culture with irradiated ECs promoted collagen deposition on
cardiomyocytes, while co-culture with L1CAM-knockdown
irradiated ECs resulted in low collagen deposition levels on
cardiomyocytes similar to those on cardiomyocytes incubated
with non-irradiated ECs (Fig. 5b, bottom). Irradiated ECs showed
higher collagen 1 expression than cardiomyocytes or non-
irradiated ECs and collagen 1 secreted from irradiated ECs may
increase collagen deposition on cardiomyocytes (Supplementary
Fig. 6d). Overall these results suggest that irradiated ECs can
directly affect cardiomyocyte function and that L1CAM expres-
sion in irradiated ECs is required for this effect.
To better define how irradiated ECs affect cardiomyocyte
dysfunction, 10 Gy-irradiated human adult cardiomyocytes
were cultured with conditioned medium from non-irradiated
and 10 Gy-irradiated ECs (Supplementary Fig. 8e). Conditioned
medium from non-irradiated ECs significantly increased the
expression levels of brain natriuretic peptide (BNP) and cardiac
troponin I (TNI) in irradiated human adult cardiomyocytes,
but conditioned media from irradiated ECs did not (Supple-
mentary Fig. 8e), suggesting that secretory factors from ECs
may affect irradiated cardiomyocyte dysfunction following
irradiation. It has been reported that Neuregulin-1 (NRG-1),
a angiocrine secreted from cardiac EC, plays a critical role in
the protection of cardiomyocytes52,53. NRG-1 increased BNP
and TNI expression in irradiated cardiomyocytes (Supplemen-
tary Fig. 8e). Coincidently, endothelial-specific NRG-1 expres-
sion in irradiated hearts was prominently decreased compared
to that in non-irradiated hearts, whereas Ab417-treated
irradiated hearts did not exhibit decreased NRG expression
(Supplementary Fig. 8f). Furthermore, RNA-seq analysis of
Fig. 1c showed that the expression of NRG-1 was significantly
reduced in 10 Gy-irradiated cells 72 h after irradiation com-
pared to 10 Gy-irradiated cells 5 h after irradiation or in non-
Fig. 3 An anti-L1CAM antibody prevents p53 knockout- and radiation-induced DNA damage in heart ECs. a RT-qPCR analysis of L1CAM in p53-
knockdown HUVECs 48 h post-irradiation (10 Gy). Error bars represent mean ± SD from three independent experiments (p < 0.0001). b Immunoblotting
(upper panel) and quantification (lower panel) of full-length L1CAM and L1-CT 48 h post-irradiation (10 Gy) in p53-knockdown HUVECs pre-treated with
control IgG or Ab417 (20 µg/mL). Error bars represent mean ± SD from four independent experiments (full-length L1CAM: No IR vs. si-Control IR+ IgG
p= 0.0468; si-Control IR+ IgG vs. si-Control IR+Ab417 p= 0.0468; si-Control IR+ IgG vs. si-p53 IR+ IgG p= 0.0462; si-p53 IR+ IgG vs. si-p53 IR+
Ab417 p= 0.0218, L1-CT: No IR vs. si-Control IR+ IgG p= 0.0124; si-Control IR+ IgG vs. si-Control IR+Ab417 p= 0.0484; si-Control IR+ IgG vs. si-p53
IR+ IgG p= 0.0206; si-p53 IR+ IgG vs. si-p53 IR+Ab417 p= 0.0004). c Immunofluorescence staining (upper panel) and quantification (lower panel) for
γ-H2AX and L1-CT. The results of quantification of γ-H2AX foci, nuclear L1CAM, and colocalization of γ-H2AX foci with L1CAM are shown (magnification,
×400). Scale bar= 5 μm. Error bars represent mean ± SEM (No. γ-H2AX foci: si-Control vs. si-p53+IgG p= 0.0107; si-p53+IgG vs. si-p53+Ab417 p=
0.0242, No. L1-CT foci: si-Control vs. si-p53+IgG p= 0.0425; si-p53+IgG vs. si-p53+Ab417 p= 0.0119, No. colocalized foci: si-Control vs. si-p53+ IgG
p= 0.0131; si-p53+ IgG vs. si-p53+Ab417 p= 0.0097). For quantification of foci colocalized with L1CAM, the colocalized foci in each sample were
counted in at least 70 cells per field (magnification, ×100, n= 5). d, e Wild-type or EC-p53KO mice were injected intravenously with control IgG or Ab417
(10mg/kg) and subjected to 17.5 Gy thoracic irradiation (n= 5 animals per group). d Immunofluorescence staining (upper panels) for γ-H2AX, L1CAM,
and CD31 in heart tissues 3 weeks post-irradiation and quantification (lower panels) of γ-H2AX+ cells and nuclear L1CAM+ cells among CD31+ cells
(magnification, ×400). Scale bar= 5 μm. Error bars represent mean ± SEM (γ-H2AX+ in CD31+ nuclei: WT+IR vs. p53KO+IR p= 0.0005; p53KO+ IgG
vs. p53KO+Ab417 p < 0.0001, L1CAM+ in CD31+ nuclei: WT+IR vs. p53KO+IR p= 0.0001; p53KO+IgG vs. p53KO+Ab417 p= 0.0002). e
Haematoxylin and eosin staining, Masson’s trichrome staining, and immunohistochemical detection of CD31 in heart tissues 3 weeks post-irradiation
(upper panels) and quantification of ventricular inflammation, perivascular fibrosis area, and microvessel density per field (magnification, ×200; lower
panels). Scale bar= 100 μm. Error bars represent mean ± SEM (ventricular inflammation: No IR vs. WT IR+ IgG p= 0.0003; WT IR+ IgG vs. WT IR+
Ab417 p= 0.0125; WT IR+ IgG vs. p53KO IR+ IgG p= 0.0104, perivascular fibrosis area: No IR vs. WT IR+ IgG p= 0.0021; WT IR+ IgG vs. WT IR+
Ab417 p= 0.0328; WT IR+ IgG vs. p53KO IR+ IgG p= 0.0203; WT IR+ IgG vs. WT IR+Ab417 p= 0.0165, MVD: No IR vs. WT IR+ IgG p < 0.0001;
WT IR+ IgG vs. WT IR+Ab417 p= 0.0055; WT IR+ IgG vs. WT IR+Ab417 p= 0.0068). f Immunofluorescence staining (left panels) of α-SMA and
CD31 in heart tissues 3 weeks post-irradiation (n= 5 animals per group) and quantification (right panels) of the α-SMA+CD31+ area in the CD31+ area
(magnification, ×400). Scale bar= 20 μm. Error bars represent mean ± SEM (No IR vs. WT IR+ IgG p < 0.0001; WT IR+ IgG vs. WT IR+Ab417 p=
0.0251; WT IR+ IgG vs. p53KO IR+ IgG p= 0.011; p53KO IR+ IgG vs. p53KO IR+Ab417 p= 0.0004). g Immunofluorescence staining (left panel) of
WGA, cTnT, and CD31 (n= 5 animals per group) and quantification (right panel) of the cTnT area per field (magnification, ×400). Scale bar= 20 μm. Error
bars represent mean ± SEM (No IR vs. WT IR+ IgG p= 0.0014; WT IR+ IgG vs. WT IR+Ab417 p= 0.0489; WT IR+ IgG vs. p53KO IR+ IgG p= 0.0253;
p53KO IR+ IgG vs. p53KO IR+Ab417 p= 0.001). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns: not significant (a Two-way ANOVA for multiple
comparisons; all other panels: one-way ANOVA for multiple comparisons).
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irradiated cells (Supplementary Fig. 8g). From these results, we
suggest that irradiated ECs reduce cardiac angiocrine NRG-1 to
protect against irradiated cardiomyocyte dysfunction, whereas
Ab417 treatment can restore this reduced angiocrine function.
Considering the above results, we next investigated whether
radiation- and Dox-induced cardiotoxicity can be mitigated by
the anti-L1CAM mAb. Compared with the survival of IgG-
treated mice, the survival of Ab417-treated mice was prolonged
after whole-heart irradiation with 16 Gy (Fig. 5c). Echocardio-
graphy showed that Ab417 markedly prevented radiation-
induced LV dysfunction, as the FS and left ventricular ejection
fraction (LVEF) were higher in Ab417-treated mice than in
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IgG-treated mice. However, left ventricular end systolic volume
(LVESV) and left ventricular end diastolic volume (LVEDV)
were lower in Ab417-treated mice than in IgG-treated mice
(Fig. 5d). In addition, Ab417 significantly prevented radiation-
induced myocardial dilation, and the cross-sectional area in the
Ab417-treated group was similar to that observed in non-
irradiated myocardium (Fig. 5e). Similar to the results observed
in irradiated mice, Ab417 treatment markedly prolonged the
50% survival rate to 100 days after Dox treatment, whereas all
mice treated with IgG and Dox died within 40 days after Dox
treatment (Fig. 5f). Ab417 also prevented the Dox-induced
decrease in LVEF (Fig. 5g). Finally, compared with
untreated control mice, Dox-treated mice showed significantly
reduced cardiomyocyte diameters; however, Ab417 treatment
almost completely prevented this decrease (Fig. 5h). Collec-
tively, these results suggest that irradiated ECs directly induce
cardiomyocyte damage and Ab417 can prevent radiation- and
Dox-induced cardiotoxicity.
The anti-L1CAM antibody enhances radiation- and Dox-
induced anti-tumour effects. To further validate the effects of
the anti-L1CAM antibody on tumours, we investigated the effects
of Ab417 treatment and radiotherapy or Dox treatment on
tumour growth in nude mice bearing metastatic breast carcinoma
MDA-MB-231 xenografts. Compared to that in non-treated
tumours, L1CAM expression significantly increased in MDA-
MB-231 tumours treated with either irradiation or Dox (Sup-
plementary Fig. 9a, b). Compared to IgG control mice, Ab417-
treated mice exhibited approximately 41% tumour growth inhi-
bition at 31 days after irradiation (Supplementary Fig. 9a).
Additionally, Ab417 treatment significantly enhanced Dox-
induced anti-tumour effects (Supplementary Fig. 9b). These
results indicate that Ab417 increases anti-tumour effects in
combination with radiation therapy and Dox treatment.
Additionally, to address whether the effects of L1CAM on
cancer cells differed from those on normal ECs, we compared
L1CAM expression in MDA-MB-231 cells and HUVECs.
L1CAM expression was found to be higher in MDA-MB-231
cells than in HUVECs (Supplementary Fig. 10a, b). However, EC-
L1CAM was highly suppressed under normal conditions and
upregulated later (48 h after irradiation) (Supplementary Fig. 10a).
In contrast to MDA-MB-231 cells, in HUVECs, we found that
Myc expression was peaked at 1 h after irradiation during DNA
damage checkpoint signalling, and then degraded. At 48 h, L1cam
expression was significantly induced, and Myc expression was
again increased in normal ECs (Supplementary Fig. 10b). These
different L1CAM expression may contribute to the contrasting
roles of L1CAM in cancer cells and normal ECs. From these
results, we suggest that Ab417 not only can prevent DNA
damage-induced cardiotoxicity without interfering with the anti-
tumour effects, rather than enhancing anti-tumour effects.
The anti-L1CAM antibody has therapeutic potential for DNA
damage-induced cardiotoxicity. Next, we aimed to evaluate if
Ab417 could be used as a therapeutic treatment by assessing if it
specifically accumulates in irradiated, damaged cardiac tissues but
no in non-damaged cardiac tissues. To this end, mouse hearts
were focally irradiated with an ablative high dose of 90 Gy using a
3-mm collimator. As expected, focally irradiated cardiac tissues
showed extensive vessel damage, including inflammation, vas-
cular destruction, and collagen accumulation; in addition, nuclear
L1-CT was markedly observed in ECs of irradiated cardiac tissue
(Supplementary Fig. 11a). To detect Ab417 accumulation, we
radiolabelled Ab417 with 64Cu to obtain 64Cu-NOTA-Ab41736
and intravenously injected 64Cu-NOTA-Ab417 into mice that
were focally irradiated with 90 Gy. Positron emission tomo-
graphy/computed tomography (PET/CT) scans revealed that
64Cu-NOTA-Ab417 accumulated specifically in irradiated hearts
(Supplementary Fig. 11b). From these results, we suggest that
Ab417 specifically accumulates in irradiation-damaged cardiac
tissues via increased L1CAM expression.
To evaluate the clinical relevance of our findings, we analysed
vascular L1CAM expression in cardiac tissues from patients with
cardiomyopathy (n= 12) compared with that in normal cardiac
tissues (n= 8). Although the patients did not receive radiotherapy
Fig. 4 An anti-L1CAM antibody (Ab417) inhibits irradiation (IR)- and Dox-induced vascular DNA damage and perivascular fibrosis with L1CAM
nuclear localisation, EndMT and cardiac TnT loss. a–e Mice were injected intravenously with control IgG or Ab417 (10mg/kg) three times a week for
2 weeks and received 16 Gy thoracic IR (No IR n= 7; IR+ IgG n= 8; IR+Ab417 n= 8). f–j Mice were injected intravenously with control IgG or Ab417
(10mg/kg) with or without intraperitoneal Dox injection (4mg/kg) three times a week for 2 weeks (No Dox n= 7; Dox+IgG n= 8; Dox+Ab417 n= 8).
a, f Immunohistochemical detection (left panels) of L1-CT and γ-H2AX in heart tissues 1 week post IR (a) and 2 weeks after Dox treatment (f). The
quantified L1-CT+ cells and γ-H2AX+ cells among ECs are shown (magnification, ×200; right panels). Scale bar= 50 μm. Error bars represent mean ± SEM
(L1-CT: IR+ IgG vs. IR+Ab417 p= 0.0004, γ-H2AX: No IR vs. IR+ IgG p= 0.0076; IR+ IgG vs. IR+Ab417 p= 0.0017; Dox+ IgG vs. Dox+Ab417 p=
0.0003, **** p < 0.0001). b, g Haematoxylin and eosin staining, Masson’s trichrome staining, and immunohistochemical detection of CD31 in heart tissues
(left panels); and quantification of arterial wall thickness, perivascular fibrosis area, and microvessel density per field in heart tissues (magnification, ×200;
right panels). Scale bar= 100 μm. The arrow in b indicates inflammatory cell infiltration. Error bars represent mean ± SEM (Arterial wall thickness: No IR vs.
IR+ IgG p < 0.0001; IR+ IgG vs. IR+Ab417 p= 0.0159; No Dox vs. Dox p= 0.0009; Dox+ IgG vs. Dox+Ab417 p= 0.0117, perivascular fibrosis area: No
IR vs. IR+ IgG p= 0.0011; IR+ IgG vs. IR+Ab417 p= 0.0168; No Dox vs. Dox p= 0.0001; Dox+ IgG vs. Dox+Ab417 p= 0.0492, MVD: No IR vs. IR+
IgG p= 0.0012; IR+ IgG vs. IR+Ab417 p= 0.0184; No Dox vs. Dox p= 0.0093; Dox+ IgG vs. Dox+Ab417 p= 0.0378). c, h Serum CRP, E-selectin, and
ICAM-1 levels 1 week post IR (c) and 1 week after Dox treatment (h). Error bars represent mean ± SD (CRP: No IR vs. IR+ IgG p < 0.0001; IR+ IgG vs. IR+
Ab417 p= 0.0015; No Dox vs. Dox p= 0.0007; Dox+IgG vs. Dox+Ab417 p= 0.0003, E-selectin: No IR vs. IR+ IgG p= 0.0031; IR+ IgG vs. IR+Ab417
p= 0.02; No Dox vs. Dox p= 0.0003; Dox+IgG vs. Dox+Ab417 p= 0.0082, ICAM-1: No IR vs. IR+ IgG p= 0.0053; IR+ IgG vs. IR+Ab417 p= 0.01; No
Dox vs. Dox p= 0.0154). d, i Immunofluorescence detection (upper panel) of L1-CT and CD31 in mouse heart tissues 1 week post IR (d) and 2 weeks after
Dox treatment (i) (magnification, ×400). Scale bar= 5 μm. Quantification of L1CAM in CD31 nuclei (lower panel). Error bars represent mean ± SEM (No IR
vs. IR+ IgG p= 0.0012; IR+ IgG vs. IR+Ab417 p= 0.0033; No Dox vs. Dox p < 0.0001; Dox IgG vs. Dox+Ab417 p= 0.0004). e, j Immunofluorescence
staining of α-SMA and CD31 (scale bar= 10 μm) and of WGA and cTnT (scale bar= 20 μm) in heart tissues 1 week post IR (e) and 2 weeks post Dox
treatment (j) (magnification, ×400; upper panels). Quantification of the α-SMA+CD31+ area in the CD31+ area and quantification of the cTnT area per
field (lower panels). Error bars represent mean ± SEM (SMA+CD31+ area in the CD31+ area: No IR vs. IR+ IgG p < 0.0001; IR+ IgG vs. IR+Ab417 p=
0.0011; No Dox vs. Dox p= 0.0013; Dox+ IgG vs. Dox+Ab417 p= 0.0103, cTnT area: No IR vs. IR+ IgG p= 0.0019; IR+ IgG vs. IR+Ab417 p= 0.0107;
No Dox vs. Dox p= 0.0126; Dox+ IgG vs. Dox+Ab417 p= 0.0494, one-way ANOVA for multiple comparisons). Data are representative of three
independent experiments.
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or Dox treatment, we selected tissues with vascular DNA damage
foci (n= 8). Compared with tissues that did not exhibit DNA
damage (n= 4) and normal cardiac tissues, patient tissues with
increased γ-H2AX foci showed significantly higher levels of nuclear
L1CAM foci in vascular ECs (Fig. 6a, b). Moreover, significantly
higher numbers of nuclear L1CAM foci were found in patient
tissues with α-SMA+ CD31+ cells indicative of EndMT (Fig. 6c).
These results confirm that L1-CT accumulates in the nuclei of
vascular ECs of patients with cardiomyopathy, suggesting that
Ab417 might be useful in these patients.
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Discussion
The common chemotherapy drug Dox and radiation therapy
induces DNA damage and cardiotoxicity, and no therapy is
currently available. In the present study, we found that nuclear
L1-CT regulates persistent DNA damage in vascular ECs during
the development of radiation- and Dox-induced cardiotoxicity
and that anti-L1CAM antibody prevents DNA damage-induced
cardiotoxicity. In vascular ECs, colocalization of L1-CT and γ-
H2AX foci appeared to regulate persistent DNA damage. Nucleus
L1-CT foci was also colocalized with DNA repair enzymes. Pre-
treatment with an anti-L1CAM antibody significantly reduced
nuclear L1-CT localisation in vascular ECs and the subsequent
vascular damage caused by radiation and Dox treatment. Fur-
thermore, nuclear colocalization of L1-CT and γ-H2AX foci was
inhibited by the γ-secretase inhibitor L-685,458 and by intro-
duction of a mutation in the NLS or RSLE motif of L1CAM. The
results suggest that γ-secretase-mediated cleavage of L1CAM and
nuclear translocation of L1-CT are required for colocalization of
L1-CT and γ-H2AX foci, which results in vascular damage after
radiation or Dox treatment. We are the first to suggest that
L1CAM regulates DNA damage via colocalization with persistent
γ-H2AX foci. The numbers of nuclear L1CAM foci were corre-
lated with the total numbers of γ-H2AX foci.
In this study, we showed that the intensity and size of foci were
increased after 24 h of irradiation. This finding might reflect the
minor population of DNA damage from the irradiation, as well as
the outcome of secondary celluar processes. The inability to
repair DNA damage at telomeric regions is a major conrtibutor to
a persistent DDR54. Moreover, DSB can also be formed indirectly
from base excision repair (BER) of clustered lesions, DNA
replication of SSB-containg templates or from transcription
processes55. Therefore, various causes might contribute to the late
occurrence of γ-H2AX foci.
The direct effects of Ab417 on L1CAM were investigated. In a
previous report36, Ab417 was found to decrease the membrane
L1CAM levels via L1CAM endocytosis; in our study, we similarly
showed that Ab417 internalisation induced the endocytotic
lysosomal degradation of membrane full-length L1CAM, which
reduced L1CAM expression and subsequently reduced the
expression of the L1-CT fragment. Furthermore, in vivo, we
found that the 64Cu-labelled anti-L1CAM antibody specifically
marked focally irradiated heart regions, indicating that the anti-
L1CAM antibody efficiently attenuates radiation-induced cardiac
damage and can prevent cardiac damage. Dox and radiation
treatments each induced a significant deterioration of cardiac
function parameters, including FS, LVEF, LVESV and LVEDV,
which was prevented by treatment with the anti-L1CAM anti-
body. Notably, anti-L1CAM antibody treatment prolonged sur-
vival after radiation or Dox treatment by preventing cardiac
dysfunction.
Ab417 regulates the L1CAM expression level that regulates
malignant transition. L1CAM expression is tightly regulated in
chemoresistant cells undergoing EMT56. HIF-1a and TGF-β1 are
EMT regulators that also regulate L1CAM expression in cancer
cells57. TGF-β1-induced L1CAM expression is related to apop-
totic resistance and promotes the malignant transition of intest-
inal epithelial cells58. Our previous study showed that the
radiation-induced EndMT process is mainly regulated by HIF-
1a and TGF-β1 in normal ECs38. Thus, increased L1CAM
expression after radiation may also be a part of natural
mechanisms to survive with irreparable DNA damage, promoting
EndMT. Ab417-treated cells exhibited reduced radiation-induced
aneuploidy of normal cells, suggesting that Ab417 can regulate
tumorigenic changes in DNA-damaged normal cells.
After radiation treatment, normal ECs appear as flattened cells
with enlarged nuclei, exhibit a fibrotic phenotype and have a
developed cytoskeleton37,38. As we have previously shown, these
characteristics are accompanied by radiation-induced EndMT
and associated tissue hypoxia38. In this study, we observed that
persistent DNA damage in ECs associated with a fibrotic phe-
notype caused EndMT. Previous studies have supported this
observation, as EndMT of cardiovascular cells has been reported
to cause various types of cardiac dysfunction such as cardiac
fibrosis and cardiomyopathy59–61. Indeed, we found that radia-
tion- and Dox-induced EndMT may be correlated with tissue
hypoxia and concurrent processes of cardiomyocyte damage, such
as loss of TnT. In irradiated EC-p53KO mice, the numbers of L1-
CT and DNA damage foci were markedly increased in ECs,
consistent with EndMT and significant loss of cTnT in cardio-
myocytes. Consistent with this possibility, our data indicate that
EndMT of cardiovascular ECs may cause loss of function in iPSC-
CMs co-cultured with irradiated ECs compared to non-irradiated
ECs, leading to increased collagen I deposition on the extra-
cellular matrix of co-cultured iPSC-CMs. Additionally, dysfunc-
tion of iPSC-CMs may be affected by co-culture with irradiated
ECs showing increased collagen expression. Consistent with our
findings, the extracellular matrix of cardiomyocytes has been
reported to play a crucial role in cardiac homoeostasis62–64, and
Fig. 5 An anti-L1CAM antibody (Ab417) mitigates irradiation (IR)- and Dox-induced cardiotoxicity and increases survival. a, b Co-culture of iPSC-CMs
and irradiated ECs transfected with control or L1CAM siRNA. a Schematic of the procedure for co-culture of iPSC-CMs and irradiated ECs. ECs were
transfected with control or L1CAM-specific siRNA and irradiated with 10 Gy. Forty-eight hours after IR, the ECs were co-cultured with iPSC-CMs (top). The
beating rates of the iPSC-CMs were examined after 5 days of co-culture with irradiated ECs (bottom). Error bars represent mean ± SD (No IR vs. si-Control
+IR p= 0.0005; si-Control+IR vs. si-L1CAM+ IR p > 0.0001). b Immunofluorescence staining (left panel) and quantification (right panel) of cTnT
expression in cardiomyocytes and the collagen I deposition area in co-cultured cells (magnification, ×200). Scale bar= 50 μm. Error bars represent mean ±
SD (cTnT expression: No IR vs. si-Control+IR p= 0.0239; si-Control+IR vs. si-L1CAM+ IR p= 0.0475, collagen I deposition: No IR vs. si-Control+ IR p=
0.027; si-Control+ IR vs. si-L1CAM+ IR p= 0492). c–e Mice were injected intravenously with control IgG or Ab417 (10mg/kg) three times a week for
2 weeks and received 16 Gy thoracic IR. f–h Mice were injected intravenously with control IgG or Ab417 (10mg/kg) with or without intraperitoneal Dox
injection (4mg/kg) three times a week for 2 weeks. c, f Cumulative survival analysis measured in days after treatment (n= 8 animals per group). d, g
Echocardiography results (upper panels) and quantification (lower panels) of FS (%), LVEF (%), LVESV (μL), and LVEDV (μL) (No IR n= 10; IR+ IgG n=
5, IR+Ab417 n= 5; No Dox n= 10; Dox+IgG n= 5, Dox+Ab417 n= 5). Scale bar= 1 mm. Error bars represent mean ± SD (FS: No IR vs. IR+ IgG p=
0.0331; IR+ IgG vs. IR+Ab417 p= 0.0172; Dox+IgG vs. Dox+Ab417 p= 0.0046, LVEF: No IR vs. IR+ IgG p= 0.0284; IR+ IgG vs. IR+Ab417 p=
0.0182; Dox+ IgG vs. Dox+Ab417 p= 0.0027, LVEDV: No IR vs. IR+ IgG p= 0.0099; IR+ IgG vs. IR+Ab417 p= 0.0054; No Dox vs. Dox p= 0.0003;
Dox+ IgG vs. Dox+Ab417 p= 0.003, LVESV: No IR vs. IR+ IgG p= 0.0005; IR+ IgG vs. IR+Ab417 p= 0.0002, ****p < 0.0001). e, h Haematoxylin and
eosin–stained ventricular myocardium (upper panels) and quantification (lower panels) of cardiomyocyte cross-sectional area (No IR n= 7; IR+ IgG n= 8;
IR+Ab417 n= 8; No Dox n= 7; Dox+ IgG n= 8; Dox+Ab417 n= 8) (magnification, ×400). Scale bar= 20 μm. Error bars represent mean ± SEM (No IR
vs. IR+ IgG p= 0.0003; IR+ IgG vs. IR+Ab417 p= 0.0002; No Dox vs. Dos+IgG p= 0.024; Dox+ IgG vs. Dox+Ab417 p= 0.0493). (a, d: log-rank
Mantel-Cox test; all other panels: one-way ANOVA for multiple comparisons).
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the imbalance of collagen deposition in the cardiac interstitium
may cause systolic dysfunction63. Furthermore, an increase in
collagen deposition has been reported to cause cardiomyocyte
dysfunction64.
Next, Ab417 targeting of L1CAM in ECs reduced DNA
damage, vascular EndMT, hypoxia, and cTNT loss in vivo after
Dox treatment or radiation. Thus, we theorise that DNA
damage in ECs may cause vascular dysfunction arising from
EndMT, subsequently increasing hypoxia and reducing the
cTnT level in cardiomyocytes, ultimately affecting overall heart
function.
Additionally, we focused on the effects of cardiac angiocrine
factors, such as NRG-1, on cardiomyocyte protection. It has been
reported that cardiac angiocrines, secretory factors of ECs,
mediate EC-CM interactions by paracrine signalling65. Of these
cardiac angiocrines, NRG-1 is known to protect cardiomyocytes
from ischaemic injury and chemotherapeutic agents52,53. Secre-
tory factors from normal ECs, but not those from irradiated ECs
Fig. 6 Nuclear L1CAM localisation with vascular EndMT and γ-H2AX L1CAM colocalization in heart tissues from patients with cardiomyopathy.
a Immunofluorescence staining of L1CAM and VE-cadherin in heart tissues from patients with cardiomyopathy (n= 12) and patients without
cardiomyopathy (n= 8) (magnification, ×400). Scale bar= 10 μm (enlarged, 2 μm). Error bars represent mean ± SEM (p= 0.0004).
b Immunofluorescence staining of γ-H2AX and CD31 in heart tissues from patients with cardiomyopathy and patients without cardiomyopathy (upper
panels) and quantification (lower panel) of nuclear L1CAM+ cells among CD31+ cells (magnification, ×400). Scale bar= 10 μm (enlarged, 2 μm). Error
bars represent mean ± SEM (Normal vs. γ-H2AX+ CD31+ p > 0.0001; γ-H2AX‒ CD31+ vs. γ-H2AX+ CD31+ p= 0.0003) c Immunofluorescence staining
of L1CAM, α-SMA, and CD31 in heart tissues from patients with cardiomyopathy and from patients without cardiomyopathy (upper panels) and
quantification (lower panel) of nuclear L1CAM+ cells among α-SMA-CD31+ and α-SMA+CD31+ cells (magnification, ×400). Scale bar= 10 μm (enlarged,
2 μm). Error bars represent mean ± SEM (p > 0.0001). (a two-tailed student’s t-test; b, c one-way ANOVA for multiple comparisons).
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undergoing EndMT, can reduce cardiomyocyte damage. In par-
ticular, our findings suggest that the angiocrine NRG-1 can
protect cardiomyocytes from irradiation.
Furthermore, we investigated whether the L1-CT and DNA
damage responses associated with cardiac damage have clinical
relevance by utilising tissues from patients with other cardiac
diseases. Our data revealed that cardiovascular ECs with persis-
tent DNA damage showed upregulated L1CAM expression with
increased EndMT occurrence, which can be attributed to the
development of cardiomyopathy. Indeed, cardiac EndMT has
been reported to affect cardiac fibrosis, cardiovascular disease,
and cardiomyopathy59,60,66. Therefore, these findings indicate
that the anti-L1CAM mAb may be a potential therapeutic agent
for regulation of cardiomyopathy.
In addition to the potential use of this antibody for cardi-
omyopathy, we recently demonstrated that combining Ab417
treatment with gemcitabine or cisplatin treatment enhances
tumour growth inhibition in cholangiocarcinoma36. Moreover,
we have reported the antitumor effects of a murine anti-
L1CAM mAb on intrahepatic cholangiocarcinoma67 and the
feasibility of radioimmunotherapy using radiolabelled anti-
L1CAM antibody in cholangiocarcinoma68. Our data also
showed that Ab417 markedly enhanced the anti-tumour effects
of radiation and Dox treatment, indicating that Ab417 can
prevent cardiotoxicity by enhancing the efficacy of anticancer
therapy. However, the differential function of L1CAM in
tumour and normal cells remains undefined. It seems that
cancer cells including MDA-MB-231 cells exhibit aberrant
expression of L1CAM. Furthermore, in glioblastoma multi-
forme (GBM) cancer cells, highly expressed L1CAM was pre-
viously found to increase DNA damage checkpoint activation
by NBS1 upregulation via c-MYC 3 h after radiation, resulting
in radioresistance33. However, in ECs, L1CAM and c-Myc
expression was upregulated after induction, and L1CAM and r-
H2AX colocalized in the late stage (48 h after radiation) in our
study, indicating persistent DNA damage. According to recent
reports, Myc influences genomic instability in normal
cells69,70. Therefore, we cautiously hypothesise that
the opposite responses of L1CAM in tumour cells and normal
ECs may be due to the dual nature of Myc (i.e., checkpoint
signalling activation and survival in cancer cells vs. genomic
instability in normal cells). However, the nature of these dif-
ferential mechanisms of L1CAM and the precise interactions
between L1-CT and colocalized DNA damage repair
proteins remain unclear, and we are currently investigating
these topics in another study. Nevertheless, we have shown
that regulation of vascular DNA damage via targeting of
endothelial L1CAM can attenuate radiation- and Dox-induced
cardiotoxicity.
Collectively, our findings support L1CAM-targeted therapy as
a potential strategy to overcome the irreparable and persistent
DNA damage that occurs during the development of cardio-
toxicity from radiation or chemotherapeutic agents, including
Dox. In particular, the use of an L1CAM-targeted antibody that
prevents the nuclear translocation of L1CAM may be a novel
strategy to prevent cardiotoxicity during DNA damage-based
anticancer therapy. Further studies on the precise molecular
mechanisms underlying the role of vascular L1CAM in DNA
damage will aid in the development of novel therapeutic strategies
for cardiac diseases.
Methods
Mice and ethical approval. All animal experiments were approved by the Insti-
tutional Animal Care and Use Committee of the Korea Institute of Radiological &
Medical Sciences (Kirams 2016-0039, 2017-0007) and are reported in accordance
with the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines.
Specific pathogen-free female BALB/c nude mice were purchased from Orient Bio.
Specific pathogen-free C57BL/6 Tie2-Cre and Trp53flox/flox mice were purchased
from the Jackson Laboratory. Male Tie2-Cre and Tie2-Cre;Trp53flox/+ mice were
crossed with female Trp53flox/flox mice to generate Tie2-Cre;Trp53flox/+ and Tie2-
Cre;Trp53flox/flox mice, respectively. Tie2-Cre;Trp53+/+ or Tie2-Cre‒/‒ littermates
were used as controls. All animal experimental data provided are representative of
three independent experiments. All experiments were conducted with 6–8-week-
old mice, and the mice were maintained on a 12 h light-dark cycle in a standard
environment (20 ± 1 °C room temperature, 50 ± 10 % relative humidity) with a
standard diet and water ad libitum. All mice were anaesthetised with a combination
of anaesthetics before being euthanized.
Human tissue specimens. Cardiac tissues (n= 14) were purchased from OriGene.
Six patients tissues of Normal #3-Normal #8 were obtained from Heart tissue array
(US Biomax, BC30013). Eight patients (five male and three female) showed normal
clinicopathological characteristics, and twelve exhibited cardiomyopathy (four
males and eight females; Supplementary Table 1).
Production of Ab417. The antibody Ab4 was selected from a human naive Fab
library, and Ab4M was generated by increasing the affinity of Ab4 45-fold via
mutation of three residues in the complementarity-determining regions (CDRs).
Next, the human anti-L1CAM mAb Ab417 was generated by increasing the affinity
of Ab4M via yeast display of scFv containing randomly mutated light chain CDR3.
Ab417 was found to be cross-reactive with mouse L1CAM35.
The anti-L1CAM antibody Ab41735 was purified from the culture supernatants
of transfected CHO cells. Cells expressing Ab417 were cultured in MEM-α
(WELGENE) supplemented with 5% (v/v) dialysed FBS (Thermo Fisher Scientific)
under 5% CO2, and the medium was changed to serum-free medium (SFM4CHO,
GE Life Sciences) for antibody production. The culture supernatant was
centrifuged and filtered using a Sartolab bottle-top filter (0.22 µm, PES; Sartorius)
and then subjected to affinity chromatography on a protein A-agarose column
(GenScript) for purification. The protein A-bound antibodies were eluted using 0.1
M sodium citrate containing 150 mM sodium chloride (pH 3.6). The eluted
antibodies were stored after a buffer change to 25 mM sodium citrate containing
150 mM sodium chloride and 0.007% Tween 20 (pH 6.4). The protein
concentrations were determined using a NanoDrop 2000 UV-Vis
Spectrophotometer (Thermo Fisher Scientific).
Mouse experiments. Mice were randomly assigned to each group. To establish a
Dox-induced cardiotoxicity model, mice were intraperitoneally injected with Dox
(4 mg/kg, 6 times/2 weeks); controls were injected with the vehicle. To establish a
radiation-induced cardiotoxicity model, the thoracic cavities of mice were irra-
diated with 16 Gy (BALB/c nude mice) using the X-RAD 320 platform (Precision
X-ray). Ab417 (10 mg/kg, 6 times/2 weeks) was injected intravenously into BALB/c
nude mice 1 h before the start of Dox or radiation treatment. Control mice were
administered an equivalent dose of an isotype control antibody (IgG). The serum
concentrations of CRP (catalogue no. MCRP00; R&D Systems), E-selectin, and
ICAM-1 (catalogue no. ab171182 and ab100688; Abcam) were measured using
mouse Quantikine ELISA kits.
Echocardiography. Cardiac function was assessed using a high-resolution echo-
cardiography system (Vivid 7; GE Medical Systems). Mice were anaesthetised using
a mixture of Zoletil (30 mg/kg) and Rompun (10 mg/kg) via intraperitoneal
injection. The percentage of LV fractional shortening (FS) was calculated using M-
mode. The LVEF percentage was calculated as [(diastolic volume− systolic
volume)/diastolic volume] × 100. Three different cardiac cycles were measured for
each assessment.
Histology and immunohistochemistry. Tissues were fixed in 10% (v/v) neutral-
buffered formalin, embedded in paraffin, and sectioned. The sections were
deparaffinized and stained as previously described38. Collagen deposition was
assessed using Masson’s trichrome stain (Sigma-Aldrich). Haematoxylin and
eosin–stained slides were analysed to score the grade of ventricular inflammation.
Histological scores were determined as follows: grade 0, no inflammation; grade 1,
<10% of the heart section infiltrated; grade 2, 10–30%; grade 3, 30–50%; grade 4,
50–90%; and grade 5, >90%. At least five images per section were acquired for
quantification, and the positively stained areas were evaluated using ImageJ soft-
ware 1.49 v. (http://imagej.net/).
Antibodies for immunoblotting and immunohistochemistry. Immunoblotting,
immunohistochemistry, and immunofluorescence staining were performed using
primary antibodies against the N-terminal domain of L1CAM (immunohis-
tochemistry/immunofluorescence 1:100; sc-31032; Santa Cruz Biotechnology), L1-
CT (immunohistochemistry/immunofluorescence 1:500, immunoblotting 1:1000;
LS-B9803; LSBio; immunofluorescence 1:200; sc-53386; Santa Cruz Biotechnology;
immunofluorescence 1:200; ab123990; Abcam), complete L1CAM (immunoblot-
ting 1:1000; sc-53386; Santa Cruz Biotechnology), γ-H2AX (immunohistochem-
istry/immunofluorescence 1:500, immunoblotting 1:1000; 05-636; Millipore), CD31
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(immunohistochemistry/immunofluorescence 1:200; #AF3628; R&D Systems;
immunoblotting 1:1000; 28364; Abcam), GAPDH (immunoblotting 1:1000; sc-
47724; Santa Cruz Biotechnology), lamin B (immunoblotting 1:1000; sc-6216;
Santa Cruz Biotechnology), αSMA (1:2000; A5228; Sigma-Aldrich), VCAM-1
(immunoblotting 1:1000; sc-1504; Santa Cruz Biotechnology), p-ATM (immuno-
fluorescence 1:200; 05-740; Millipore), 53BP1 (immunofluorescence 1:200; sc-
10914; Santa Cruz Biotechnology), and DNA-PKcs (immunofluorescence 1:200; sc-
135886; Santa Cruz Biotechnology). To visualise actin stress fibres, cells were
stained with Alexa Fluor 488-conjugated phalloidin (1:40; Invitrogen), which
specifically binds polymerised F-actin. At least five images per section were
acquired for quantification, and the positively stained areas were evaluated
using ImageJ.
Cell culture and treatments. HUVECs (#C-12203) and human CD14+mono-
cytes (#C-12909) were obtained from PromoCell and cultured in Endothelial Cell
Growth Medium 2 and Mononuclear Cell Medium (PromoCell), respectively,
under 5% CO2. For silencing experiments, cells were transfected with siRNAs
targeting TP53 and L1CAM, as well as control siRNA (Santa Cruz Biotechnology)
using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instruc-
tions. Cells were irradiated with γ-rays from a 137Cs source (Atomic Energy of
Canada) at 3.81 Gy/min or treated with 0.5 μM Dox. Before irradiation or Dox
treatment, the cells were pre-treated with the anti-L1CAM antibody Ab417 (20 μg/
mL) for 1 h or treated with 3 μM of the γ-secretase inhibitor L-685,458 (sc-204042;
Santa Cruz Biotechnology). For analysis of cellular proteins, immunocytochemistry
was performed as previously described38. Cytoplasmic and nuclear proteins were
extracted using NE-PERTM Nuclear and Cytoplasmic Extraction Reagents (#78833;
Thermo Fisher Scientific).
RT-qPCR analysis. RNA was isolated using TRI reagent (MRC), after which 1 µg
of RNA was used to synthesise cDNA with an Omniscript RT Kit (Qiagen). PCR
was conducted in triplicate using a CFX96TM Real-Time PCR Detection System
(Bio-Rad Laboratories) and qPCR SYBR Green Master Mix (Invitrogen). For each
sample, the target gene expression was normalised against the geometric mean of
the expression of the reference gene GAPDH. The following primers were used:
L1CAM (NM_000425) forward, 5ʹ- GGTTCGTTCATTGGCCAGTACAGT -3ʹ,
and reverse, 5ʹ- GTCAGGGAGCAAGAAAGACAGCAT -3ʹ; and GAPDH
(NM_002046) forward, 5ʹ-CGAGATCCCTCCAAAATCAA-3ʹ, and reverse, 5ʹ-
CCTTCTCCATGGTGGTGAA-3ʹ.
RNA-seq analysis. Total RNA was isolated from HUVECs, and RNA quality was
assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies). RNA-seq
libraries were constructed using an NEBNext Ultra II Directional RNA-Seq Kit
(New England Biolabs, Inc., UK) according to the manufacturer’s instructions and
were sequenced in 100 bp paired-end runs using a HiSeq X10 platform (Illumina,
Inc., USA). The RNA-seq reads were mapped to University of California, Santa
Cruz (UCSC) genome hp19 using TopHat software. Genes with a maximal log2-
transformed read count <3 across samples were excluded from the analysis. We
used the criterion of a | log2(fold change, FC) | > 1 to identify the differentially
expressed genes by comparing the irradiated group to the non-irradiated group.
EndMT-related genes among the differentially expressed genes were displayed in R
using the pheatmap package (v1.0.12). The RNA-seq data generated in this study
are available in the Gene Expression Omnibus (GEO, accession number
GSE155285).
HR/NHEJ assay. The plasmids pHPRT-DR-GFP, pimEJ5GFP, and pBAD-I-SceI
(#26476, #44026, and #60960, respectively; Addgene)46–48 were kindly donated by
Dr. Chang-Woo Lee (Department of Molecular Cell Biology, Sungkyunkwan
University School of Medicine). pHPRT-DR-GFP or pimEJ5GFP was transfected
into HUVECs along with control or L1CAM-targeting siRNA using Lipofectamine
2000 reagent (Invitrogen). After 1 day, the cells were transfected with pBAD-I-SceI
to induce DNA damage and cultured for 48 h. The cells positive for GFP because of
DNA repair were analysed on a FACSCalibur flow cytometer (Becton Dickinson,
Franklin Lakes, NJ) to estimate the frequencies of HR and NHEJ. Gating strategy
for flow cytometry analysis was shown in Supplementary Figure 12.
Co-culture of iPSC-CMs and ECs. iPSC-CMs were purchased from Cellartis
(#Y50025) and cultured in 50 μg/mL fibronectin-coated dishes according to the
manufacturer’s protocols. HUVECs were transfected with control or L1CAM-
targeting siRNA using Lipofectamine 2000 reagent (Invitrogen). Forty-eight hours
after seeding (5 × 103 cells), irradiated HUVECs or non-irradiated HUVECs were
co-cultured with iPSC-CMs for 5 days in 35 mm confocal dishes. The cell seeding
density of the iPSC-CMs (alone and in co-cultures) was 4 × 105 cells/dish (1:80
ratio for iPSC-CMs:HUVECs). The ECs were labelled with the tracking dye PKH26
(Sigma # PKH26GL). The cells were cultured at 37 under 5% CO2 in culture
medium (iPSC-CMs: MiraCell® CM Culture Medium v2). The medium was
changed after 2 days. Images of beating iPSC-CMs were obtained with a micro-
scope and were measured for 1 min. Cells were fixed in 10% (v/v) neutral-buffered
formalin and subjected to TnT and collagen staining for immunofluorescence
analysis.
Statistical analysis. The data are expressed as the means ± SDs or SEMs. A log-
rank test was used for the survival assay, unpaired Student’s t-test was used to
analyse differences between two groups, and one-way ANOVA followed by Tukey’s
multiple comparisons test was used for multiple comparisons (>2 groups). p-values
< 0.05 were considered to indicate statistical significance. Statistical analysis was
performed using GraphPad Prism version 7.0. The experimenters were blinded to
the group assignments and outcome assessments. We used Image J 1.49 v (NIH), R
4.0.4, Zen 3.2 (Zeiss) and Diva 7.0 (BD Biosciences) for data and image analysis
and plotting.
Additional information is available in the Supplementary Methods.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The RNA-seq data was deposited in Gene Expression Omnibus (GEO) with accession
number “GSE155285”. All other relevant data are available from the corresponding
author upon reasonable request. Source data are provided with this paper.
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